Clinical trial data from the  Second International Breast Cancer Intervention Study (IBIS-II) suggest a reduction in breast cancer risk using aromatase inhibitors (AI) in women with increased risk.16 However, there is no direct evidence to support a benefit for this approach in BRCA1 mutation carriers. The gene discussed is CYP19A1; the disease is breast cancer.